PERINDOPRIL ARGININE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C19H32N2O5.C6H14N4O2
Molecular Weight	542.6687
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

N[C@@H](CCCNC(N)=N)C(O)=O.[H][C@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O

InChI

InChIKey=RYCSJJXKEWBUTI-YDYAIEMNSA-N

InChI=1S/C19H32N2O5.C6H14N4O2/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24;7-4(5(11)12)2-1-3-10-6(8)9/h12-16,20H,4-11H2,1-3H3,(H,23,24);4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t12-,13-,14-,15-,16-;4-/m00/s1

HIDE SMILES / InChI

Molecular Formula	C6H14N4O2
Molecular Weight	174.201
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C19H32N2O5
Molecular Weight	368.4678
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	5 / 5
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17519062 | https://www.medicines.org.uk/emc/product/6224/smpc | https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205003s000lbl.pdf

Perindopril arginine is a stable L-arginine salt of perindopril. Perindopril, a pro-drug, is hydrolyzed to perindoprilat, which inhibits ACE in humans and in animals. It is indicated for the treatment of hypertension, heart failure and coronary artery disease. Perindopril arginine may be used in monotherapy or in combination with other classes of antihypertensive therapy.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Angiotensin-converting enzyme 97 Target ID: CHEMBL1808 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1457697 \| https://www.medicines.org.uk/emc/product/6224/smpc \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205003s000lbl.pdf	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Hypertension 567 Sources: https://adisinsight.springer.com/drugs/800032076	Primary	Approved 8429	PRESTALIA Approved Use Prestalia is a combination of perindopril arginine, an angiotensin converting enzyme inhibitor, and amlodipine besylate, a dihydropyridine calcium channel blocker, indicated for the treatment of hypertension to lower blood pressure Launch Date 2015
Heart failure 103 Sources: https://www.medicines.org.uk/emc/product/6224/smpc	Primary	Approved 8429	Coversyl Arginine Approved Use Hypertension: Treatment of hypertension. Heart failure: Treatment of symptomatic heart failure. Stable coronary artery disease: Reduction of risk of cardiac events in patients with a history of myocardial infarction and/or revascularisation.
Coronary artery disease 48 Sources: https://www.medicines.org.uk/emc/product/6224/smpc	Primary	Approved 8429	Coversyl Arginine Approved Use Hypertension: Treatment of hypertension. Heart failure: Treatment of symptomatic heart failure. Stable coronary artery disease: Reduction of risk of cardiac events in patients with a history of myocardial infarction and/or revascularisation.

C_max

Value	Dose	Analyte	Population
15 ng/mL OTHER https://pdf.hres.ca/dpd_pm/00044188.PDF	2.5 mg 1 times / day steady-state, oral dose: 2.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PERINDOPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
26 ng/mL OTHER https://pdf.hres.ca/dpd_pm/00044188.PDF	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PERINDOPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
61 ng/mL OTHER https://pdf.hres.ca/dpd_pm/00044188.PDF	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PERINDOPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
16 ng/mL OTHER https://pdf.hres.ca/dpd_pm/00044188.PDF	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PERINDOPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
3.8 ng/mL OTHER https://pdf.hres.ca/dpd_pm/00044188.PDF	2.5 mg 1 times / day steady-state, oral dose: 2.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PERINDOPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
8.3 ng/mL OTHER https://pdf.hres.ca/dpd_pm/00044188.PDF	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PERINDOPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED

AUC

Value	Dose	Analyte	Population
17 ng × h/mL OTHER https://pdf.hres.ca/dpd_pm/00044188.PDF	2.5 mg 1 times / day steady-state, oral dose: 2.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PERINDOPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
34 ng × h/mL OTHER https://pdf.hres.ca/dpd_pm/00044188.PDF	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PERINDOPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
69 ng × h/mL OTHER https://pdf.hres.ca/dpd_pm/00044188.PDF	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PERINDOPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
127 ng × h/mL OTHER https://pdf.hres.ca/dpd_pm/00044188.PDF	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PERINDOPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
52 ng × h/mL OTHER https://pdf.hres.ca/dpd_pm/00044188.PDF	2.5 mg 1 times / day steady-state, oral dose: 2.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PERINDOPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
81 ng × h/mL OTHER https://pdf.hres.ca/dpd_pm/00044188.PDF	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PERINDOPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED

T_1/2

Value	Dose	Analyte	Population
0.42 h OTHER https://pdf.hres.ca/dpd_pm/00044188.PDF	2.5 mg 1 times / day steady-state, oral dose: 2.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PERINDOPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
0.45 h OTHER https://pdf.hres.ca/dpd_pm/00044188.PDF	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PERINDOPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
0.42 h OTHER https://pdf.hres.ca/dpd_pm/00044188.PDF	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PERINDOPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED

Doses

Dose	Population	Adverse events
14 mg 1 times / day multiple, oral Dose: 14 mg, 1 times / day Route: oral Route: multiple Dose: 14 mg, 1 times / day Co-administed with:: amlodipine(10 mg QD; 6 weeks) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205003Orig1s000MedR.pdf Page: 205003Orig1s000MedR.pdf p.85	unhealthy, 65-75 years n = 279 Health Status: unhealthy Condition: hypertension Age Group: 65-75 years Sex: M+F Population Size: 279 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205003Orig1s000MedR.pdf Page: 205003Orig1s000MedR.pdf p.85	Disc. AE: Gravitational oedema, Cough... AEs leading to discontinuation/dose reduction: Gravitational oedema (1.8%) Cough (0.4%) Dizziness (0.4%) Fatigue (0.4%) Irritability (0.4%) Pulmonary embolism (0.4%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205003Orig1s000MedR.pdf Page: 205003Orig1s000MedR.pdf p.85
180 mg 1 times / day single, oral Dose: 180 mg, 1 times / day Route: oral Route: single Dose: 180 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205003s000lbl.pdf	unhealthy n = 1 Health Status: unhealthy Condition: hypertension Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205003s000lbl.pdf	Other AEs: Hypothermia, Circulatory failure... Other AEs: Hypothermia Circulatory failure Death Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205003s000lbl.pdf

AEs

AE	Significance	Dose	Population
Cough	0.4% Disc. AE	14 mg 1 times / day multiple, oral Dose: 14 mg, 1 times / day Route: oral Route: multiple Dose: 14 mg, 1 times / day Co-administed with:: amlodipine(10 mg QD; 6 weeks) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205003Orig1s000MedR.pdf Page: 205003Orig1s000MedR.pdf p.85	unhealthy, 65-75 years n = 279 Health Status: unhealthy Condition: hypertension Age Group: 65-75 years Sex: M+F Population Size: 279 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205003Orig1s000MedR.pdf Page: 205003Orig1s000MedR.pdf p.85
Dizziness	0.4% Disc. AE	14 mg 1 times / day multiple, oral Dose: 14 mg, 1 times / day Route: oral Route: multiple Dose: 14 mg, 1 times / day Co-administed with:: amlodipine(10 mg QD; 6 weeks) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205003Orig1s000MedR.pdf Page: 205003Orig1s000MedR.pdf p.85	unhealthy, 65-75 years n = 279 Health Status: unhealthy Condition: hypertension Age Group: 65-75 years Sex: M+F Population Size: 279 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205003Orig1s000MedR.pdf Page: 205003Orig1s000MedR.pdf p.85
Fatigue	0.4% Disc. AE	14 mg 1 times / day multiple, oral Dose: 14 mg, 1 times / day Route: oral Route: multiple Dose: 14 mg, 1 times / day Co-administed with:: amlodipine(10 mg QD; 6 weeks) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205003Orig1s000MedR.pdf Page: 205003Orig1s000MedR.pdf p.85	unhealthy, 65-75 years n = 279 Health Status: unhealthy Condition: hypertension Age Group: 65-75 years Sex: M+F Population Size: 279 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205003Orig1s000MedR.pdf Page: 205003Orig1s000MedR.pdf p.85
Irritability	0.4% Disc. AE	14 mg 1 times / day multiple, oral Dose: 14 mg, 1 times / day Route: oral Route: multiple Dose: 14 mg, 1 times / day Co-administed with:: amlodipine(10 mg QD; 6 weeks) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205003Orig1s000MedR.pdf Page: 205003Orig1s000MedR.pdf p.85	unhealthy, 65-75 years n = 279 Health Status: unhealthy Condition: hypertension Age Group: 65-75 years Sex: M+F Population Size: 279 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205003Orig1s000MedR.pdf Page: 205003Orig1s000MedR.pdf p.85
Pulmonary embolism	0.4% Disc. AE	14 mg 1 times / day multiple, oral Dose: 14 mg, 1 times / day Route: oral Route: multiple Dose: 14 mg, 1 times / day Co-administed with:: amlodipine(10 mg QD; 6 weeks) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205003Orig1s000MedR.pdf Page: 205003Orig1s000MedR.pdf p.85	unhealthy, 65-75 years n = 279 Health Status: unhealthy Condition: hypertension Age Group: 65-75 years Sex: M+F Population Size: 279 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205003Orig1s000MedR.pdf Page: 205003Orig1s000MedR.pdf p.85
Gravitational oedema	1.8% Disc. AE	14 mg 1 times / day multiple, oral Dose: 14 mg, 1 times / day Route: oral Route: multiple Dose: 14 mg, 1 times / day Co-administed with:: amlodipine(10 mg QD; 6 weeks) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205003Orig1s000MedR.pdf Page: 205003Orig1s000MedR.pdf p.85	unhealthy, 65-75 years n = 279 Health Status: unhealthy Condition: hypertension Age Group: 65-75 years Sex: M+F Population Size: 279 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205003Orig1s000MedR.pdf Page: 205003Orig1s000MedR.pdf p.85
Circulatory failure		180 mg 1 times / day single, oral Dose: 180 mg, 1 times / day Route: oral Route: single Dose: 180 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205003s000lbl.pdf	unhealthy n = 1 Health Status: unhealthy Condition: hypertension Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205003s000lbl.pdf
Death		180 mg 1 times / day single, oral Dose: 180 mg, 1 times / day Route: oral Route: single Dose: 180 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205003s000lbl.pdf	unhealthy n = 1 Health Status: unhealthy Condition: hypertension Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205003s000lbl.pdf
Hypothermia		180 mg 1 times / day single, oral Dose: 180 mg, 1 times / day Route: oral Route: single Dose: 180 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205003s000lbl.pdf	unhealthy n = 1 Health Status: unhealthy Condition: hypertension Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205003s000lbl.pdf

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:77655	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:77655
ChemicalBook	CB32694358	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB32694358

PubMed

Title	Date	PubMed
Perindopril arginine: benefits of a new salt of the ACE inhibitor perindopril.	2007 May	17519062

Patents

Sample Use Guides

In Vivo Use Guide

Hypertension: The recommended starting dose is 5 mg given once daily in the morning. Patients with a strongly activated renin-angiotensin-aldosterone system (in particular, renovascular hypertension, salt and/or volume depletion, cardiac decompensation or severe hypertension) may experience an excessive drop in blood pressure following the initial dose. A starting dose of 2.5 mg is recommended in such patients and the initiation of treatment should take place under medical supervision. The dose may be increased to 10 mg once daily after one month of treatment. Symptomatic heart failure: It is recommended that Coversyl Arginine, generally associated with a non-potassium-sparing diuretic and/or digoxin and/or a beta-blocker, be introduced under close medical supervision with a recommended starting dose of 2.5 mg taken in the morning. This dose may be increased after 2 weeks to 5 mg once daily if tolerated. The dose adjustment should be based on the clinical response of the individual patient. Stable coronary artery disease: Coversyl Arginine should be introduced at a dose of 5 mg once daily for two weeks, then increased to 10 mg once daily, depending on renal function and provided that the 5 mg dose is well tolerated.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Sat Dec 16 01:47:38 GMT 2023` Edited by `admin` on `Sat Dec 16 01:47:38 GMT 2023`
Record UNII	TFT5IM1KGB
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PERINDOPRIL ARGININE

Common Name

English

Perindopril Arginine [WHO-DD]

Common Name

English

L-ARGININE, (2S,3AS,7AS)-1-((2S)-2-(((1S)-1-(ETHOXYCARBONYL)BUTYL)AMINO)-1-OXOPROPYL)OCTAHYDRO-1H-INDOLE-2-CARBOXYLATE (1:1)

Common Name

English

PERINDOPRIL ARGININE [ORANGE BOOK]

Common Name

English

COVERSYL

Common Name

English

Code System Code Type Description

DRUG BANK

DBSALT001144